Beijing Aikang Weijian Medical Technology Co., Ltd.

The study was conducted on healthy subjects taking 600 mg of acetylcysteine effervescent tablets orally after meals to evaluate whether the test preparation (600 mg of acetylcysteine effervescent tablets produced by Jianqiao Plant of Jianqiao Xinyuan Pharmaceutical Biotechnology Co., Ltd.) and the reference preparation (600 mg of acetylcysteine effervescent tablets produced by ZAMBON S.P.A., Italy, trade name: Fluluciz) were bioequivalent, to provide a basis for the effectiveness and safety of the drug in clinical application, and to provide a reference for production and rational clinical use of the drug.

The study of oral administration of 600 mg of acetylcysteine effervescent tablets on fasting subjects was conducted to evaluate whether the test preparation (600 mg of acetylcysteine effervescent tablets produced by Jianqiao Plant of Jianqiao Xinyuan Pharmaceutical Biotechnology Co., Ltd.) and the reference preparation (600 mg of acetylcysteine effervescent tablets produced by ZAMBON S.P.A. of Italy, trade name: Flulucit) were bioequivalent, to provide a basis for the effectiveness and safety of the drug in clinical application, and to provide a reference for production and rational clinical use of the drug.

By taking 600 mg of acetylcysteine effervescent tablets orally after meals to healthy subjects, the bioequivalence of the test preparation (600 mg of acetylcysteine effervescent tablets produced by Jianqiao Plant of Jianqiao Xinyuan Pharmaceutical Biotechnology Co., Ltd.) and the reference preparation (600 mg of acetylcysteine effervescent tablets produced by ZAMBON S.P.A. of Italy, trade name: Flulucite) was evaluated, so as to provide a basis for the effectiveness and safety of the clinical application of the drug and a reference for the production and rational use of the drug in clinical practice.